Do These 3 Checks Before Buying Farmaceutica REMEDIA S.A. (BVB:RMAH) For Its Upcoming Dividend
Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Farmaceutica REMEDIA S.A. (BVB:RMAH) is about to trade ex-dividend in the next three days. The ex-dividend date is two business days before a company's record date in most cases, which is the date on which the company determines which shareholders are entitled to receive a dividend. The ex-dividend date is important because any transaction on a stock needs to have been settled before the record date in order to be eligible for a dividend. This means that investors who purchase Farmaceutica REMEDIA's shares on or after the 14th of September will not receive the dividend, which will be paid on the 30th of September.
The company's next dividend payment will be RON00.05 per share, on the back of last year when the company paid a total of RON0.05 to shareholders. Based on the last year's worth of payments, Farmaceutica REMEDIA has a trailing yield of 6.0% on the current stock price of RON00.832. If you buy this business for its dividend, you should have an idea of whether Farmaceutica REMEDIA's dividend is reliable and sustainable. So we need to check whether the dividend payments are covered, and if earnings are growing.
Dividends are usually paid out of company profits, so if a company pays out more than it earned then its dividend is usually at greater risk of being cut. Farmaceutica REMEDIA paid out 120% of profit in the past year, which we think is typically not sustainable unless there are mitigating characteristics such as unusually strong cash flow or a large cash balance. Yet cash flows are even more important than profits for assessing a dividend, so we need to see if the company generated enough cash to pay its distribution.
It's disappointing to see that the dividend was not covered by profits, but cash is more important from a dividend sustainability perspective, and Farmaceutica REMEDIA fortunately did generate enough cash to fund its dividend. If executives were to continue paying more in dividends than the company reported in profits, we'd view this as a warning sign. Extraordinarily few companies are capable of persistently paying a dividend that is greater than their profits.
Check out our latest analysis for Farmaceutica REMEDIA
Click here to see how much of its profit Farmaceutica REMEDIA paid out over the last 12 months.
Have Earnings And Dividends Been Growing?
Companies with falling earnings are riskier for dividend shareholders. If earnings decline and the company is forced to cut its dividend, investors could watch the value of their investment go up in smoke. Farmaceutica REMEDIA's earnings per share have plummeted approximately 35% a year over the previous five years.
Many investors will assess a company's dividend performance by evaluating how much the dividend payments have changed over time. Farmaceutica REMEDIA has seen its dividend decline 20% per annum on average over the past five years, which is not great to see. While it's not great that earnings and dividends per share have fallen in recent years, we're encouraged by the fact that management has trimmed the dividend rather than risk over-committing the company in a risky attempt to maintain yields to shareholders.
The Bottom Line
Has Farmaceutica REMEDIA got what it takes to maintain its dividend payments? It's looking like an unattractive opportunity, with its earnings per share declining, while, paying out an uncomfortably high percentage of both its profits (120%) and cash flow as dividends. This is a clearly suboptimal combination that usually suggests the dividend is at risk of being cut. If not now, then perhaps in the future. With the way things are shaping up from a dividend perspective, we'd be inclined to steer clear of Farmaceutica REMEDIA.
Having said that, if you're looking at this stock without much concern for the dividend, you should still be familiar of the risks involved with Farmaceutica REMEDIA. Our analysis shows 4 warning signs for Farmaceutica REMEDIA that we strongly recommend you have a look at before investing in the company.
Generally, we wouldn't recommend just buying the first dividend stock you see. Here's a curated list of interesting stocks that are strong dividend payers.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.